Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person* Parschauer Karah Herdman (Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT						Susuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE] 3. Date of Earliest Transaction (Month/Day/Year) 10/08/2020										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) EVP and General Counsel					
(Street)	Street) NOVATO CA 94949							4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transa Date									e, Transaction Disposed (Code (Instr. 5)				of, or Beneficially ities Acquired (A) or d Of (D) (Instr. 3, 4 and			5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock					8/2020				4	Code M(1)	v	Amount (A) or (D) or 10,000 A 10,000 D		\$54.5 \$95	Transact (Instr. 3	34,293 24,293 ⁽²⁾		D D	(1134. 4)		
		Derivati (e.g., pu di Ti Date, CC 8)	ive Securities Acquits, calls, warrants 5. Number of of Derivative		6. Da Expi (Mor	tired, Disposed of, options, convertile 6. Date Exercisable and Expiration Date (Month/Day/Year)		or Beneficia ble securities 7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4) Amou or Numb		icially ties) Amount ecurity 4)		9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)						
Stock Option	\$54.5	10/08/2020			М			10,000		(3)	0	6/20/2026	Commo	n 1	0.000	\$0.00	35,00	0	D		

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

- 2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- 3. The option vested with respect to 1/4th of the shares on June 20, 2017 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option fully vested on the fourth anniversary of the grant date.

Remarks:

(Right to Buy)

/s/ Karah Parschauer

Stock

10/13/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.